Marcia Rubia Rodrigues Gonçalves

Marcia Rubia Rodrigues Gonçalves

Auto-generated profile, based on publicly available information

Marcia Rubia Rodrigues Gonçalves

Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia, São Paulo SP, Brazil

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
ASAdalberto Studart-Neto
Adalberto Studart-Neto
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RTRaphael de Luca e Tuma
Raphael de Luca e Tuma
ACAntonio Edvan Camelo-Filho
Antonio Edvan Camelo-Filho
GKGabriel Taricani Kubota
Gabriel Taricani Kubota
RNRicardo Nitrini
Ricardo Nitrini
Background: More than one-third of COVID-19 patients present neurological symptoms ranging from anosmia to stroke and encephalopathy. Furthermore, pre-existing neurological conditions may require special treatment and may be associated with worse outcomes. Notwithstanding, the role of neurologists in COVID-19 is probably underrecognized. Objective: The aim of this study was to report the reasons for requesting neurological consultations by internists and intensivists in a COVID-19-dedicated hospital. Methods: This retrospective study was carried out at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil, a 900-bed COVID-19 dedicated center (including 300 intensive care unit beds). COVID-19 diagnosis was confirmed by SARS-CoV-2-RT-PCR in nasal swabs. All inpatient neurology consultations between March 23rd and May 23rd, 2020 were analyzed. Neurologists performed the neurological exam, assessed all available data to diagnose the neurological condition, and requested additional tests deemed necessary. Difficult diagnoses were established in consensus meetings. After diagnosis, neurologists were involved in the treatment. Results: Neurological consultations were requested for 89 out of 1,208 (7.4%) inpatient COVID admissions during that period. Main neurological diagnoses included: encephalopathy (44.4%), stroke (16.7%), previous neurological diseases (9.0%), seizures (9.0%), neuromuscular disorders (5.6%), other acute brain lesions (3.4%), and other mild nonspecific symptoms (11.2%). Conclusions: Most neurological consultations in a COVID-19-dedicated hospital were requested for severe conditions that could have an impact on the outcome. First-line doctors should be able to recognize neurological symptoms; neurologists are important members of the medical team in COVID-19 hospital care.

7 January 2021 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
RTRaphael L. Tuma
Raphael L. Tuma
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RCRafael Bernhart Carra
Rafael Bernhart Carra
BIBruno Iepsen
Bruno Iepsen
JRJúlia Rodrigues
Júlia Rodrigues
LCLuiz H. Castro
Luiz H. Castro

2 August 2018 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
IPIgor Gomes Padilha
Igor Gomes Padilha
RNR.H. Nunes
R.H. Nunes
FSF.A. Scortegagna
F.A. Scortegagna
JPJ.L. Pedroso
J.L. Pedroso
VMV.H. Marussi
V.H. Marussi
ARAntônio Jose da Rocha
Antônio Jose da Rocha
We have read with great interest the article by Sugiyama et al[1][1] published in the November 2017 edition of the American Journal of Neuroradiology , which described typical brain MR imaging findings in adult-onset neuronal intranuclear inclusion disease (NIID). The authors highlighted the

1 September 2020 in medRxiv
Verified
Preprint
Open access
PDF file
RTRaphael Tuma
Raphael Tuma
BGBruno Fukelmann Guedes
Bruno Fukelmann Guedes
RCRafael Bernhart Carra
Rafael Bernhart Carra
BIBruno Iepsen
Bruno Iepsen
JRJúlia Rodrigues
Júlia Rodrigues
LCLuiz Henrique Castro
Luiz Henrique Castro
Objective: To describe the clinical, neurological, neuroimaging and cerebrospinal fluid (CSF) findings associated with encephalopathy in patients admitted to a COVID-19 tertiary reference center. Methods: We retrospectively reviewed records of consecutive patients with COVID-19 evaluated by a consulting neurology team from March 30, 2020 through May 15, 2020. Results: Fifty-five patients with confirmed SARS-CoV-2 were included, 43 of whom showed encephalopathy, and were further divided into mild, moderate and severe encephalopathy groups. Nineteen patients (44%) had undergone mechanical ventilation and received intravenous sedatives. Eleven (26%) patients were on dialysis. Laboratory markers of COVID-19 severity were very common in encephalopathy patients, but did not correlate with the severity of encephalopathy. Thirty-nine patients underwent neuroimaging studies, which showed mostly non-specific changes. One patient showed lesions possibly related to CNS demyelination. Four had suffered an acute stroke. SARS-CoV-2 was detected by RT-PCR in only one of 21 CSF samples. Two CSF samples showed elevated white blood cell count and all were negative for oligoclonal bands. In our case series the severity of encephalopathy correlated with higher probability of death during hospitalization (OR = 5.5 for each increment in the degree of encephalopathy, from absent (0) to mild (1), moderate (2) or severe (3), p<0.001). Conclusion: In our consecutive series with 43 encephalopathy cases, neuroimaging and CSF analysis did not support the role of direct viral CNS invasion or CNS inflammation as the cause of encephalopathy.

15 January 2025 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
DMDébora Palma Maia
Débora Palma Maia
RCRubens Gisbert Cury
Rubens Gisbert Cury
Pedro Renato de Paula BrandãoPedro Renato de Paula Brandão
Pedro Renato de Paula Brandão
FCFrancisco E. C. Cardoso
Francisco E. C. Cardoso
ABAna Paula Bertholo
Ana Paula Bertholo
RSRoberta Arb Saba
Roberta Arb Saba
The treatment of Parkinson's disease (PD) is a challenge, especially because it is considered highly individualized. The Brazilian Academy of Neurology (ABN) has identified the need to disseminate knowledge about its management, adapting the best evidence to the Brazilian population. The present article aims to report the recommendations for the treatment of non-motor symptoms of PD, developed by a group of specialists in movement disorders from the ABN's scientific department. In 2021, the first part, referring to the motor symptoms of PD, was published. The main non-motor symptoms were addressed—among them neuropsychiatric symptoms, such as depression, anxiety, cognitive alteration, and psychosis—as well as the possible recommended therapies and medications used to control pain, sleep disorders, and dysautonomia.

1 January 2021
Verified
Conference Paper
Open access
PSPedro Silva
Pedro Silva
Mariana ÁvilaMariana Ávila
Mariana Ávila
MGMárcia Gonçalves
Márcia Gonçalves